Schedule 1 - Evolutec Group plc

ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES")

COMPANY NAME:

Evolutec Group plc

COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) :

3 More London Riverside, London, SE1 2AQ

COUNTRY OF INCORPORATION:

England & Wales

COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26:

www.evolutec.com

COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING STRATEGY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:

Evolutec Group plc ("Evolutec") is classed as an investment company under the AIM Rules. The investment policy of Evolutes' has been to seek a single investment, most probably of a UK or European business, in either the technology, healthcare or service related sectors.

The main country of operation is England.

The boards of Evolutec and Nanoco Tech Public Limited Company ("Nanoco") have reached agreement on the terms of recommended share acquisition by Evolutec of the entire issued and to be issued share capital of Nanoco to be effected by means of a court approved scheme of arrangement. 

Admission is sought as a result of a reverse take-over under Rule 14.

Nanoco is a leading nanotechnology company involved in the development and manufacture of fluorescent semi-conducting materials called quantum dots. Quantum dots are a platform technology with uses in a wide range of applications from life sciences through to optoeletronics dominated by solid state lighting, photovoltaics and next generation displays.

Quantum dot based applications have the ability to potentially offer significant benefits in performance and energy savings compared to those materials currently used.

DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares):

184,088,032 Ordinary Shares of 10p each

CAPITAL TO BE RAISED ON ADMISSION (IF APPLICABLE) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:

Anticipated market capitalisation upon admission - £38,658,487

PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:

83.56%

DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED:

N/A

FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known):

Directors

Dr. David Philip Bloxham - Non-Executive Chairman

Gordon James Hall - Non-Executive Director

Mark Barrie Hawtin - Non-Executive Director

Graeme Manson Hart - Non-Executive Director

Proposed Directors

Dr. Peter John Rowley - Non-Executive Chairman

Dr. Michael Albert Edelman - Chief Executive Officer

Dr. Nigel Leroy Pickett - Chief Technical Officer

Michael Anthony Bretherton - Chief Financial Officer

Upon Admission the board of the Company will comprise of the Proposed Directors and Gordon James Hall.

FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known):

Before Admission

Gartmore Investment Management Limited - 25.99%

Bluehone Investors LLP - 12.16%

Fortis Bank - 11.06%

GAM International - 10.87%

Close Asset Management - 5.07%

Charles Stanley - 4.24%

After Admission

ORA Guernsey - 36.34%

Gartmore - 16.10%

Mitsubishi UFJ - 6.45%

Nigel Pickett - 5.67%

Paul O'Brien - 5.39%

Michael Edelman - 5.03%

Manchester Tech Fund - 3.73%

Nora Powell - 3.26%

NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES:

None

ANTICIPATED ACCOUNTING REFERENCE DATE 

DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information)

DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19:

31 December

Years ended 31 December 2006, 2007 and 2008.

31 September 2009 (Interims) 31 June 2010 (Annual Accounts) 31 September 2010 (Interims)

EXPECTED ADMISSION DATE:

30 April 2009

NAME AND ADDRESS OF NOMINATED ADVISER:

Zeus Capital Limited

3 Ralli Courts

West Riverside

Manchester

M3 5FT

NAME AND ADDRESS OF BROKER:

Zeus Capital Limited

3 Ralli Courts

West Riverside

Manchester

M3 5FT

OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:

The Admission document will be available from the following address and will contain full details about the applicant and the admission of its securities;

Zeus Capital Limited

3 Ralli Courts

West Riverside

Manchester

M3 5FT

DATE OF NOTIFICATION:

2 March 2009

NEW/ UPDATE:

New